These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 10364354)

  • 1. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    Maruyama T; Rodriguez LL; Jahrling PB; Sanchez A; Khan AS; Nichol ST; Peters CJ; Parren PW; Burton DR
    J Virol; 1999 Jul; 73(7):6024-30. PubMed ID: 10364354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human monoclonal antibodies to Ebola virus.
    Maruyama T; Parren PW; Sanchez A; Rensink I; Rodriguez LL; Khan AS; Peters CJ; Burton DR
    J Infect Dis; 1999 Feb; 179 Suppl 1():S235-9. PubMed ID: 9988189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
    Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
    Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The induction and characterization of monoclonal antibodies specific to GP of Ebola virus.
    Tian X; Chen D; Wang H; Xu S; Zhu L; Wu X; Wu Z
    J Med Virol; 2020 Aug; 92(8):996-1006. PubMed ID: 31663613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
    Bramble MS; Hoff N; Gilchuk P; Mukadi P; Lu K; Doshi RH; Steffen I; Nicholson BP; Lipson A; Vashist N; Sinai C; Spencer D; Olinger G; Wemakoy EO; Illunga BK; Pettitt J; Logue J; Marchand J; Varughese J; Bennett RS; Jahrling P; Cavet G; Serafini T; Ollmann Saphire E; Vilain E; Muyembe-Tamfum JJ; Hensely LE; Simmons G; Crowe JE; Rimoin AW
    J Infect Dis; 2018 Nov; 218(12):1929-1936. PubMed ID: 30107445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
    Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW
    Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
    Rimoin AW; Lu K; Bramble MS; Steffen I; Doshi RH; Hoff NA; Mukadi P; Nicholson BP; Alfonso VH; Olinger G; Sinai C; Yamamoto LK; Ramirez CM; Okitolonda Wemakoy E; Kebela Illunga B; Pettitt J; Logue J; Bennett RS; Jahrling P; Heymann DL; Piot P; Muyembe-Tamfum JJ; Hensley LE; Simmons G
    J Infect Dis; 2018 Jan; 217(2):223-231. PubMed ID: 29253164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving cross-reactivity with pan-ebolavirus antibodies.
    King LB; Milligan JC; West BR; Schendel SL; Ollmann Saphire E
    Curr Opin Virol; 2019 Feb; 34():140-148. PubMed ID: 30884329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.
    Ksiazek TG; Rollin PE; Williams AJ; Bressler DS; Martin ML; Swanepoel R; Burt FJ; Leman PA; Khan AS; Rowe AK; Mukunu R; Sanchez A; Peters CJ
    J Infect Dis; 1999 Feb; 179 Suppl 1():S177-87. PubMed ID: 9988182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
    Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
    Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
    J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection.
    Shcheblyakov D; Esmagambetov I; Simakin P; Kostina L; Kozlov A; Tsibezov V; Grebennikova T; Chifanov D; Rumyantseva I; Boyarskaya N; Sizikova T; Shagarova N; Andrus А; Shatohina I; Syromyatnikova S; Kovalchuk A; Pantyukhov V; Borisevich S; Zubkova O; Tukhvatulin A; Logunov D; Naroditsky B; Gintsburg A
    Antiviral Res; 2019 Dec; 172():104617. PubMed ID: 31593751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
    Reynard O; Volchkov VE
    J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995.
    Busico KM; Marshall KL; Ksiazek TG; Roels TH; Fleerackers Y; Feldmann H; Khan AS; Peters CJ
    J Infect Dis; 1999 Feb; 179 Suppl 1():S102-7. PubMed ID: 9988172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.
    Sobarzo A; Perelman E; Groseth A; Dolnik O; Becker S; Lutwama JJ; Dye JM; Yavelsky V; Lobel L; Marks RS
    Clin Vaccine Immunol; 2012 Nov; 19(11):1844-52. PubMed ID: 22993411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo.
    Bratcher A; Hoff NA; Doshi RH; Gadoth A; Halbrook M; Mukadi P; Musene K; Ilunga-Kebela B; Spencer D; Bramble MS; McIlwan D; Kelly JD; Mukadi D; Kingebeni PM; Ahuka S; Okitolonda-Wemakoy E; Muyembe-Tamfum JJ; Rimoin AW
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009566. PubMed ID: 34383755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies.
    Ilinykh PA; Graber J; Kuzmina NA; Huang K; Ksiazek TG; Crowe JE; Bukreyev A
    J Infect Dis; 2018 Nov; 218(suppl_5):S418-S422. PubMed ID: 30060231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.
    Zhu W; Banadyga L; Emeterio K; Wong G; Qiu X
    Viruses; 2019 Oct; 11(11):. PubMed ID: 31683550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.